Objective: To summarize and analyze the currently published literature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Children

clinical practice guidelines or expert consensus and experience in drug therapy of SARS/MERS infection in children based on evidence-based evaluation and literature review

so as to provide evidence-based basis for the formulation of drug therapy for children with SARS-CoV-2 infection. Methods: PubMed

EMBase

the Cochrane Library

CNKI (including the special database of corona virus disease 2019)

WanFang Data

SinoMed

and the Chinese Medical Association Journal (column of prevention

control and diagnosis of SARS-CoV-2) were systematically retrieved. According to the characteristics and needs of the literature research

the rapid retrieval strategy and time limit were set up to summarize and descriptively analyze the drug therapy that met the inclusion criteria. Results: Totally 11 literature and pediatric cases reports (196 children) and 8 pediatric clinical practice guidelines or expert consensus were included. The medical therapeutic experience of children with SARS/MERS infection were reviewed. Up to now

the drug therapy regimens for reported cases were basically complied with the recommendation of SARS-CoV-2 infection guidelines for children and consistent with the previously published drug therapy experience for children with SARS/MERS. Alpha-interferon was the most commonly used and recommended. The use of other antiviral drugs mostly referred to the drug use of adults

the effectiveness and safety need to be further confirmed by clinical studies. The application of glucocorticoids and human immunoglobulins in children with severe infection was still controversial

and the pros and cons need to be weighed and used with caution. The indication of antibiotics treatment should be strictly controlled. Other treatments

such as traditional Chinese medicine

also need more supportive data. Conclusion: At present

for children with SARS-CoV-2 infection

there is no confirmed effective drug therapy regimens

which is basically consistent with the treatment experience of SARS/MERS. Development of drug therapy regimens for SARS-CoV-2 infection in children still requires further clinical trial data and experience.